drugset / Trial / NCT04004195
Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status
Non-randomizedParallel-groupOpen-labelOther
Summary
BAY2327949 is currently under clinical development for chronic kidney disease. The goal of this study is to learn more about how the body absorbs, distributes and excretes the study drug when taken once per mouth as 30mg tablet. An additional important goal of this study is to gain more information on how well the study drug is tolerated and its effect on the human body functions. The study will enroll healthy participants or patients with mild, moderate or severe reduced kidney functions matched for age, weight and gender. The results of this study will help researchers to select the best dosing of the study drug for future studies in patients.
Timeline
- Start
- 2019-07-10
- Primary completion
- 2020-02-07
- Completion
- 2020-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY2327949 | Unknown | 15 mg | Oral |
| Subject | BAY2327949 | Unknown | 30 mg | Oral |
Indications
No indication recorded.